MMP13 and breast carcinoma: Collectively, our data suggest that MMP13-selective inhibitor Cmpd-1 significantly reduces breast cancer burden at both the primary tumor site and also in bone as a secondary site, where the severity of tumor-induced bone osteolysis was also reduced.